» Articles » PMID: 28707218

The DNA Damage Response Pathway in Normal Hematopoiesis and Malignancies

Overview
Journal Int J Hematol
Specialty Hematology
Date 2017 Jul 15
PMID 28707218
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

In mammalian cells, the DNA damage response (DDR) prevents the replication and propagation of DNA errors to the next generation, thus maintaining genomic stability. At the heart of the DDR are the related signaling kinases ATM, ATR, and DNA-PK, which regulate DNA repair and associated events such as cell cycle checkpoints, chromatin remodeling, transcription, and ultimately apoptosis. Several findings highlight the occurrence of DDR in hemopoietic stem cells (HSCs), and persistence of DNA lesions in these cells promotes their functional decline and accumulation of leukemogenic mutations. Besides favoring tumor formation and progression, molecular defects that directly or indirectly inactivate certain DDR pathways can provide a therapeutic opportunity, since a reduced ability to repair DNA lesions renders hemopoietic malignancies vulnerable to genotoxic drugs acting also through synthetic lethal interactions. Here, we discuss the essential role of DDR in HSC maintenance and protection against leukemogenesis, and how acquired DDR dysfunctions or pharmacological agents that block this pathway can be effectively exploited for the treatment of various hematopoietic malignancies.

Citing Articles

Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy.

Bouchla A, Sotiropoulou C, Esteb C, Loupis T, Papageorgiou S, Deliconstantinos G Ann Hematol. 2024; 103(8):2853-2863.

PMID: 38842564 PMC: 11283411. DOI: 10.1007/s00277-024-05785-x.


Specific and shared biological functions of PARP2 - is PARP2 really a lil' brother of PARP1?.

Szanto M, Yelamos J, Bai P Expert Rev Mol Med. 2024; 26:e13.

PMID: 38698556 PMC: 11140550. DOI: 10.1017/erm.2024.14.


Progression of Notch signaling regulation of B cells under radiation exposure.

Shu X, Wang J, Zeng H, Shao L Front Immunol. 2024; 15:1339977.

PMID: 38524139 PMC: 10957566. DOI: 10.3389/fimmu.2024.1339977.


Fanca deficiency is associated with alterations in osteoclastogenesis that are rescued by TNFα.

Oppezzo A, Monney L, Kilian H, Slimani L, Maczkowiak-Chartois F, Rosselli F Cell Biosci. 2023; 13(1):115.

PMID: 37355617 PMC: 10290407. DOI: 10.1186/s13578-023-01067-7.


Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.

Niu J, Peng D, Liu L Front Oncol. 2022; 12:896426.

PMID: 35865470 PMC: 9294245. DOI: 10.3389/fonc.2022.896426.


References
1.
Inoue S, Li W, Tseng A, Beerman I, Elia A, Bendall S . Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell. 2016; 30(2):337-348. PMC: 5022794. DOI: 10.1016/j.ccell.2016.05.018. View

2.
Herriott A, Tudhope S, Junge G, Rodrigues N, Patterson M, Woodhouse L . PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget. 2015; 6(41):43978-91. PMC: 4791280. DOI: 10.18632/oncotarget.6287. View

3.
Faraoni I, Compagnone M, Lavorgna S, Angelini D, Cencioni M, Piras E . BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta. 2014; 1852(3):462-72. DOI: 10.1016/j.bbadis.2014.12.001. View

4.
Lebron C, Chen L, Gilkes D, Chen J . Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 2006; 25(6):1196-206. PMC: 1422166. DOI: 10.1038/sj.emboj.7601032. View

5.
Pearl L, Schierz A, Ward S, Al-Lazikani B, Pearl F . Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015; 15(3):166-80. DOI: 10.1038/nrc3891. View